In the European pharmaceutical industry, there were 91 M&A deals announced in Q3 2024, worth a total value of $3.8bn, according to GlobalData’s Deals Database. The $925m acquisition of Mallinckrodt by CVC Capital Partners Fund IX was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q3 2024 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, M&A activity in Europe decreased by 50% in Q3 2024 compared with the previous quarter’s total of $7.6bn and fell by 66% as compared to Q3 2023. Related deal volume decreased by 9% in Q3 2024 versus the previous quarter and was 1% higher than in Q3 2023.
The top-ranked financial advisors supporting these M&A deals in Europe in 9M 2024 were Clairfield International; PricewaterhouseCoopers International; Lazard with 7, 7, 6 deals respectively.
The top-ranked legal advisors supporting these M&A deals in Europe in 9M 2024 were CMS Legal Services EEIG; Latham & Watkins; Addleshaw Goddard with 6, 5, 4 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2024 – Strategic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.